DUBLIN--(BUSINESS WIRE)--The "North America Breast Cancer Screening Tests Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.
The major factors for the growth of North America breast cancer screening tests market include the rising incidence of breast cancer, increasing government initiatives and support, and technological advancements.
Breast cancer is currently the leading cause of cancer-related deaths in women in North America. According to the American Cancer Society, in 2017, an estimated 252,710 new cases of invasive breast cancer were diagnosed among women.
In addition, 63,410 cases of in situ breast carcinoma were diagnosed among women. Approximately 40,610 women and 460 men died from breast cancer in 2017 and furthermore, the number of breast cancer cases are expected to increase in the coming years.
Moreover, it is estimated that the risk of an individual dying from breast cancer would increase in the coming years. Hence, the increase in breast cancer prevalence is a major factor contributing to the revenue growth of the breast cancer screening tests market.
Thus, owing to the all above-mentioned factors the market is expected to witness high growth over the forecast period.
Mammograms Expected to Hold the Largest Market Share
In most of the cases of breast cancer screening, mammograms are used. The United States Preventive Services Task Force (USPSTF) recommends that women who are 50 to 74 years old and are at average risk for breast cancer get a mammogram every two years. Furthermore, mammograms are the best way to find breast cancer early, and having regular mammograms can lower the risk of dying from breast cancer.
At this time, a mammogram is the best way to find breast cancer for most women. However, there are other imaging techniques which are also gaining more popularity over the forecast period. Also, mammography is less likely to find breast tumors in women with dense breast tissue as both tumors and dense breast tissue appear white on a mammogram, it can be harder to find a tumor when there is dense breast tissue. Thus, owing to the rising cases of breast cancer in the region the market is expected to witness high growth over the forecast period.
The market studied is a moderately fragmented market owing to the presence of several small and major market players. Some of the market players are Agendia BV, Fujifilm Holdings Corporation, Hologic Inc., Metabolomic Technologies Inc., Myriad Genetics, QIAGEN NV, Quest Diagnostics Incorporated, and Siemens Healthineers.
Key Topics Covered:
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidence of Breast Cancer
4.2.2 Increasing Government Initiatives & Support
4.2.3 Technological Advancements
4.3 Market Restraints
4.3.1 Controversies Related to Mammography
4.3.2 Side-effects of Radiation during Screening Tests & Errors in Screening
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Test
5.1.1 Genomic Tests
22.214.171.124 MammaPrint Test
126.96.36.199 Breast Cancer Index Test
188.8.131.52 Mammostrat Test
184.108.40.206 PAM50 Test
220.127.116.11 Oncotype DX Test
18.104.22.168 Other Genomic Tests
5.1.2 Imaging Test
22.214.171.124 Other Imaging Tests
5.2.1 North America
126.96.36.199 United States
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Agendia B.V.
6.1.2 Fujifilm Holdings Corporation
6.1.3 Hologic Inc.
6.1.4 Metabolomic Technologies Inc.
6.1.5 Myriad Genetics
6.1.6 QIAGEN N.V.
6.1.7 Quest Diagnostics Incorporated
6.1.8 Siemens Healthineers
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/dpauo3